KBC Group’s Avidity Biosciences RNAM Stock Holding History

KBC Group’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,375	Closed	-$243K	–	1868
2025 Q4	$243K	Hold	3,375	–	–	﹤0.01%	845
2025 Q3	$147K	Hold	3,375	–	–	﹤0.01%	1043
2025 Q2	$96K	Sell	3,375 -1,099	-25%	-$32.8K	﹤0.01%	1227
2025 Q1	$132K	Hold	4,474	–	–	﹤0.01%	1323
2024 Q4	$130K	Buy	4,474 +2,226	+99%	+$93K	﹤0.01%	1375
2024 Q3	$103K	Hold	2,248	–	–	﹤0.01%	1267
2024 Q2	$92K	Buy	+2,248	New	+$64.5K	﹤0.01%	1223

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

KBC Group's RNAM Position: Q1 2026 in Review

KBC Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,375 shares — an estimated $243K sold.

KBC Group first reported a position in RNAM in Q2 2024 and held it in 7 quarters. The position peaked at $243K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

KBC Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
KBC Group sold 3,375 Avidity Biosciences shares in Q1 2026, an estimated $243K.
KBC Group first reported a position in Avidity Biosciences in Q2 2024 and held it in 7 quarters.
KBC Group's Avidity Biosciences position peaked at $243K in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.